Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 4NET 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Meningioma 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Pituitary Neoplasms 1Paraganglioma 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Brain Neoplasms 1Acromegaly 1

Interventions

pentetreotide 2Magnetic Resonance Spectroscopy 2tipifarnib 1gallium Ga 68 dotatate 1cixutumumab 1Trastuzumab 1Specimen Handling 1Salts 1Oxaliplatin 1Octreotide 1Nivolumab 1Leucovorin 1Ipilimumab 1Floxuridine 1Fentanyl 1Everolimus 1CTLA-4 Antigen 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × Octreotide × CNS × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡